D. Schenk

P. Dolan, R. Barbour, D. Schenk, 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging.

Y. Ihara, D. Schenk, K. Khan, 1999, The American journal of pathology.

Increased β‐amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation

B. Winblad, L. Lannfelt, J. Johnston, 1994, FEBS letters.

Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein.

K. Johnson-wood, L. McConlogue, I. Lieberburg, 1991, The Journal of biological chemistry.

Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages.

D. Schenk, G. Basi, Zhao Ren, 2007, The Journal of biological chemistry.

AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils

S. Kennel, R. Barbour, R. Donnell, 2012, PloS one.

Hopes remain for an Alzheimer's vaccine

D. Schenk, 2004, Nature.

Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation.

B. Winblad, D. Selkoe, D. Teplow, 1994, Proceedings of the National Academy of Sciences of the United States of America.

The potential utility of transgenic mice harboring β-amyloid precursor protein

L. McConlogue, D. Schenk, K. D. Games, 1995, Neurobiology of Aging.

Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids

D. Selkoe, R. Wolfert, C. Vigo‐Pelfrey, 1992, Nature.

Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse

M. Pangalos, R. Motter, D. Kholodenko, 2008, Neurodegenerative Diseases.

Aβ42 immunization in Alzheimer's disease generates Aβ N‐terminal antibodies

R. Black, K. Johnson-wood, P. Seubert, 2005 .

Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease

D. Schenk, W. A. Gool, P. Bolhuis, 1994, Neuroscience Letters.

Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody

D. Price, M. Voytko, D. Schenk, 1994, Journal of neuropathology and experimental neurology.

Identification of secreted beta-amyloid precursor protein binding sites on intact human fibroblasts.

K. Johnson-wood, T. Oltersdorf, I. Lieberburg, 1994, Biochemical and Biophysical Research Communications - BBRC.

Appearance of Sodium Dodecyl Sulfate-Stable Amyloid β-Protein (Aβ) Dimer in the Cortex During Aging

Y. Ihara, D. Schenk, K. Khan, 1999 .

Atrial natriuretic peptide mRNA is regulated by glucocorticoids in vivo.

J. Baxter, D. Gardner, D. Schenk, 1986, Biochemical and biophysical research communications.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

M. Liedtke, D. Seldin, M. Gertz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of Biomarkers in Clinical Trials for Alzheimer Disease

Eric M Reiman, Henrik Zetterberg, Kejal Kantarci, 2006, Alzheimer disease and associated disorders.

Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning

D. Schenk, 2002, Nature Reviews Neuroscience.

Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau (*)

J. Trojanowski, V. Lee, R. Barbour, 1995, The Journal of Biological Chemistry.

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.

D. Selkoe, D. Schenk, Dennis J Selkoe, 2003, Annual review of pharmacology and toxicology.

Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance.

Manuel Buttini, R. Barbour, P. Seubert, 2004, The American journal of pathology.

Inhibitory monoclonal antibodies against rat liver alcohol dehydrogenase.

H. Leffert, D. Schenk, P. Lad, 1984, Archives of biochemistry and biophysics.

Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease*

R. Barbour, P. Seubert, D. Schenk, 2006, Journal of Biological Chemistry.

Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease

Makoto Hashimoto, Michael Alford, E. Masliah, 2005, Neuron.

Secreted form of amyloid β protein precursor is involved in the growth regulation of fibroblasts

T. Oltersdorf, D. Schenk, D. Schubert, 1989, Cell.

The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway

D. Selkoe, L. Lannfelt, C. Lemere, 1995, Nature Medicine.

Roles in Alzheimer Disease Apolipoprotein E and Apolipoprotein E Receptors : Normal Biology and Subject Collection The Biology of Alzheimer Disease Animal Models of Alzheimer Disease

D. Holtzman, J. Cummings, D. Selkoe, 2012 .

First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers

M. Grundman, D. Schenk, W. Zago, 2016, Movement disorders : official journal of the Movement Disorder Society.

Identification of γ-Secretase Inhibitor Potency Determinants on Presenilin*

D. Schenk, K. Hu, Mike Lee, 2008, Journal of Biological Chemistry.

Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain

F. D. Miller, R. Motter, D. Kholodenko, 2000, Journal of neurochemistry.

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial

J. Jankovic, J. Quinn, M. Grundman, 2018, JAMA neurology.

A novel presenilin‐1 mutation: Increased β‐amyloid and neurofibrillary changes

J. Growdon, B. Hyman, R. Tanzi, 1997 .

Kunitz Protease Inhibitor‐Containing Amyloid β Protein Precursor Immunoreactivity in Alzheimer's Disease

B T Hyman, B. Hyman, R. Tanzi, 1992, Journal of neuropathology and experimental neurology.

Amyloid β-peptide is produced by cultured cells during normal metabolism

D. Selkoe, D. Teplow, C. Vigo‐Pelfrey, 1992, Nature.

Amyloid beta-peptide is produced by cultured cells during normal metabolism.

D. Teplow, C. Vigo‐Pelfrey, C. Haass, 1992, Nature.

Treatment strategies targeting amyloid β-protein.

M. Pangalos, D. Schenk, G. Basi, 2012, Cold Spring Harbor perspectives in medicine.

A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium

M. Weiner, M. Tuszynski, L. Schneider, 2008, Alzheimer's & Dementia.

Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease

R. Motter, R. Barbour, K. Johnson-wood, 1997 .

Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab

W. Weis, J. Saldanha, D. Schenk, 2014, Alzheimer's Research & Therapy.

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

E. Masliah, Manuel Buttini, R. Barbour, 2011, PloS one.

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

E. Masliah, E. Rockenstein, P. Seubert, 2005, Neuron.

What do people at risk for Alzheimer disease think about surrogate consent for research?

S. Gilman, D. Schenk, 2006, Neurology.

The role of microglia in Alzheimer’s disease: friend or foe?

D. Schenk, T. Yednock, 2002, Neurobiology of Aging.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

Nick C Fox, K. Blennow, E. Liu, 2009, Neurology.

Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease

Alexander K. Buell, Tuomas P. J. Knowles, Michele Vendruscolo, 2014, PloS one.

Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease

J. Langston, Manuel Buttini, L. McConlogue, 2013, PloS one.

Analysis and Quantitation of the β‐Amyloid Precursor Protein in the Cerebrospinal Fluid of Alzheimer's Disease Patients with a Monoclonal Antibody‐Based Immunoassay

W. Burke, R. Barbour, K. Johnson-wood, 1991, Journal of neurochemistry.

The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects

R. Neve, L. Benowitz, E. Mufson, 1989, Experimental Neurology.

The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II

K. Johnson-wood, T. Oltersdorf, I. Lieberburg, 1989, Nature.

Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide

L. Thal, D. Galasko, R. Barbour, 1993, Nature.

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy

E. Masliah, R. Barbour, E. Rockenstein, 2017, Acta neuropathologica communications.

Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

E. Masliah, R. Barbour, E. Rockenstein, 2014, The Journal of Neuroscience.

Immunotherapy with β-Amyloid for Alzheimer's Disease: A New Frontier

P. Seubert, D. Schenk, R. Ciccarelli, 2001 .

Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier.

D. Schenk, P. Seubert, R. Ciccarelli, 2001, DNA and cell biology.

Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model

F. Bloom, J. Morrison, R. Rydel, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer Disease

T. Comery, M. Pangalos, W. Weis, 2009, The Journal of Biological Chemistry.

Monoclonal antibodies to surfactant proteins SP28-36 label canine type II and nonciliated bronchiolar cells by immunofluorescence.

J. Lewicki, D. Schenk, M. Williams, 1988, The American review of respiratory disease.

Explorer Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease

B. Hyman, M. Meyer-Luehmann, T. Spires-Jones, 2017 .

Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease

R. Motter, D. Kholodenko, R. Barbour, 2010, Alzheimer's Research & Therapy.

Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease

B. Hyman, M. Meyer-Luehmann, T. Spires-Jones, 2009, Neurobiology of Disease.

Immunotherapy Reduces Vascular Amyloid-β in PDAPP Mice

R. Barbour, P. Seubert, D. Schenk, 2008, The Journal of Neuroscience.

Potential treatment opportunities for Alzheimer’s disease through inhibition of secretases and Aβ immunization

P. Seubert, D. Schenk, D. Games, 2001, Journal of Molecular Neuroscience.

Aβ Immunotherapy: Lessons Learned for Potential Treatment of Alzheimer’s Disease

R. Black, M. Grundman, P. Seubert, 2006, Neurodegenerative Diseases.

β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease

E. Masliah, Manuel Buttini, R. Motter, 2005, The Journal of Neuroscience.

Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpression.

S. Younkin, L. Younkin, C. Ebeling, 2004, Human molecular genetics.

Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses.

F. Bloom, J. Morrison, R. Rydel, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy

B. Hyman, B. Bacskai, P. Seubert, 2002, The Journal of Neuroscience.

Accumulation of Amyloid β-Protein in the Low-Density Membrane Domain Accurately Reflects the Extent of β-Amyloid Deposition in the Brain

Y. Ihara, D. Schenk, K. Khan, 2001 .

beta-peptide immunization: a possible new treatment for Alzheimer disease.

P. Seubert, I. Lieberburg, D. Schenk, 2000, Archives of neurology.

Aβ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse

B. Hyman, M. Irizarry, D. Schenk, 1997, The Journal of Neuroscience.

Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease

L. Mucke, E. Masliah, M. Mallory, 1996, The Journal of Neuroscience.

Chronic γ-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures

Richard M. Page, T Bonhoeffer, T. Bonhoeffer, 2013, Molecular Psychiatry.

Mice as models: transgenic approaches and Alzheimer's disease.

Manuel Buttini, P. Seubert, D. Schenk, 2006, Journal of Alzheimer's disease : JAD.

Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific

T. Comery, Manuel Buttini, P. Seubert, 2012, The Journal of Neuroscience.

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities

P. Seubert, D. Schenk, T. Guido, 2013, Alzheimer's & Dementia.

Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

E. Masliah, R. Barbour, E. Rockenstein, 2013, The American journal of pathology.

Cerebrospinal fluid levels of amyloid β‐protein in alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein e genotype

J. Growdon, B. Hyman, R. Wurtman, 1995, Annals of neurology.

Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid β-Peptide in Alzheimer’s Disease and Major Depression – Inverse Correlation with Dementia Severity

J. Growdon, R. Tanzi, R. Nitsch, 1998, European Neurology.

Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid

C. Vigo‐Pelfrey, I. Lieberburg, D. Schenk, 1993 .

Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies

C. Dobson, M. Vendruscolo, E. Mandelkow, 2015, Current Alzheimer research.

Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit

R. Brookmeyer, D. Meier, M. Naylor, 2012, Alzheimer's & Dementia.

Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

E. Masliah, L. Hansen, P. Seubert, 2005, Neurology.

Current progress in beta-amyloid immunotherapy.

P. Seubert, D. Schenk, M. Hagen, 2004, Current opinion in immunology.

Revision of the criteria for Alzheimer's disease: A symposium

Ronald C. Petersen, Richard Frank, Michael Gold, 2011, Alzheimer's & Dementia.

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.

D. Schenk, 2002, Nature reviews. Neuroscience.

Characterization of the atrial natriuretic peptide clearance receptor using a vaccinia virus expression vector.

J. Lewicki, D. Schenk, J. G. Porter, 1988, The Journal of biological chemistry.

The Aβ peptide conjugate vaccine, acc-001, generates n-terminal anti- Aβ antibodies in the absence of Aβ directed t-cell responses

P. Seubert, D. Schenk, S. Jacobsen, 2011, Alzheimer's & Dementia.

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease

L. Chang, B. Miller, C. Vigo‐Pelfrey, 1995, Neurology.

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

J. Kaye, D. Knopman, D. Galasko, 1998, Archives of neurology.

Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats

K. Davis, V. Haroutunian, C. Vigo‐Pelfrey, 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery

J. Trojanowski, M. Carrillo, D. Schenk, 2006, Alzheimer's & Dementia.

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

E. Masliah, Manuel Buttini, R. Motter, 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Characterization of beta-amyloid peptide from human cerebrospinal fluid.

C. Vigo‐Pelfrey, I. Lieberburg, D. Schenk, 1993, Journal of neurochemistry.

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

R. Black, K. Johnson-wood, P. Seubert, 2005, Annals of neurology.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting

R. R. Walsh, S. Piantadosi, J. Schmahmann, 2018, Neurology.

Amyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activity.

P. Seubert, D. Schenk, S. Wright, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide

P. Scheltens, M. Blankenstein, R. Veerhuis, 2013, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease.

R. Rydel, I. Lieberburg, D. Schenk, 1995, Journal of medicinal chemistry.

The Effect of Apolipoprotein E Genotype on Biochemical Markers of Alzheimer's Disease

R. Motter, I. Lieberburg, D. Schenk, 1996, Annals of the New York Academy of Sciences.

Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions

D. Agard, E. Masliah, G. Tóth, 2019, Scientific Reports.

Alzheimer’s Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?

D. Bennett, L. Thal, R. Petersen, 2006, Alzheimer's & Dementia.

Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease

J. Jankovic, D. Jennings, J. Quinn, 2018 .

On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid.

C. Dobson, G. Tóth, M. Vendruscolo, 2009, Biochemistry.